31 completed, 17 active not recruiting, 14 unknown, 9 recruiting. 88 Phase 2, 11 Phase 1, 7 Phase 3.
Follow Intensity-Modulated Radiotherapy: new trials by email Literature Review of Intensity-Modulated Radiotherapy trials Research Report on Intensity-Modulated Radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 298 | 2026-12-01 | 2026-10-27 |
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 214 | 2026-12-01 | 2026-10-29 |
| Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2) - HPV-unrelated Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 104 | 2026-09-01 | 2026-08-20 |
| Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Becotatug Vedotin, Toripalimab, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-04-20 | 2026-04-29 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection - Basal Ganglia Germinoma, Diabetes Insipidus | Phase 2 | Recruiting | Children's Oncology Group | 240 | 2024-10-22 | 2026-08-25 |
| Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study Intensity-modulated radiotherapy, Immunotherapy Therapy - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Zhongnan Hospital | 25 | 2024-08-08 | 2025-03-24 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma Biopsy, Biospecimen Collection, Computed Tomography - Retroperitoneal Sarcoma | Phase 1 / Phase 2 | Recruiting | Northwestern University | 28 | 2024-04-02 | 2026-07-07 |
| Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy - Esophagus Cancer | Phase 2 | Active not recruiting | Sun Yat-sen University | 46 | 2024-03-02 | 2026-04-23 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
| Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy Trifluridine/Tipiracil, intensity-modulated radiotherapy - Rectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 65 | 2024-01-01 | 2025-04-29 |
| Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC Intensity-modulated radiotherapy, Magnetic Resonance Guidance - Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 35 | 2023-12-14 | 2026-04-01 |
| Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma Iron Isomaltoside 1000, Polysaccharide Iron Complex Pill, Intensity-modulated radiotherapy - Nasopharyngeal Carcinoma, Iron-deficiency | Phase 2 | Unknown | Sun Yat-sen University | 120 | 2023-05-05 | 2023-06-22 |
| De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA Biospecimen Collection, Cisplatin, Computed Tomography - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 455 | 2023-03-20 | 2026-10-01 |
| Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Paclitaxel, Cisplatin, tislelizumab, Radiotherapy - Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Sun Yat-sen University | 114 | 2022-09-15 | 2024-11-18 |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-10-05 |
| Umbrella Biomarker-Guided Therapy in NPC GP+DDP, Palbociclib, Intensity-modulated radiotherapy - Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 206 | 2022-06-01 | 2021-09-05 |
| Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma Camrelizumab, Gemcitabine, Induction Cisplatin - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Wei Jiang | 200 | 2022-04-06 | 2023-03-23 |
Showing 20 of 88. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (13) · Nasopharyngeal Carcinoma (11) · Esophageal Squamous Cell Carcinoma (7) · Oropharyngeal Neoplasms (6) · Carcinoma (5) · Gliosarcoma (5) · Hypopharyngeal Neoplasms (5) · Laryngeal Neoplasms (5) · Mouth Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Squamous Cell (4) · Glioblastoma (4) · Head and Neck Neoplasms (4) · Nasopharyngeal Neoplasms (4) · Prostatic Neoplasms (4)
National Cancer Institute (NCI) (14) · Sun Yat-sen University (12) · M.D. Anderson Cancer Center (8) · Mayo Clinic (7) · NRG Oncology (7) · ECOG-ACRIN Cancer Research Group (4) · Albert Einstein College of Medicine (3) · Chinese Academy of Medical Sciences (3) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Fudan University (2) · Mian XI (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · Dana-Farber Cancer Institute (1) · Emory University (1)
United States (55) · China (25) · Canada (16) · Australia (4) · Hong Kong (3) · Puerto Rico (3) · Saudi Arabia (2) · Ireland (1) · Israel (1) · New Zealand (1) · Singapore (1) · Taiwan (1)
Guopei Zhu, M.D. (3) · Mian Xi, MD (2) · Akila Viswanathan (1) · Alejandro Sanchez (1) · Ashish Chintakuntlawar (1) · Bin Zhang, M.D. (1) · Brian J. Davis, M.D. (1) · Chao Zhou, MD. (1) · Charles Catton, MD (1) · Cy A Stein (1) · Dan P Zandberg (1) · Daniel Ma (1) · David M Brizel (1) · David M, Routman, M.D. (1) · David R Grosshans (1)
PMID 36990609, PMID 35355438, PMID 22178121, PMID 24309981, PMID 25105369, PMID 25113840, PMID 25847373, PMID 26163437, PMID 27152857, PMID 27701653, PMID 28317872, PMID 30642373, PMID 31163012, PMID 31545689, PMID 31996395, PMID 32009149, PMID 32126267, PMID 33051340, PMID 33096027, PMID 33102224, PMID 33507809, PMID 33571520, PMID 33608212, PMID 33771703, PMID 33842889, PMID 34196693, PMID 34351356, PMID 34454674, PMID 34519801, PMID 34632876, PMID 34749885, PMID 35080076, PMID 35108470, PMID 35419831, PMID 36221952, PMID 36681089, PMID 37195667, PMID 37266942, PMID 37478389, PMID 37560259, PMID 37797632, PMID 37852261, PMID 38197800, PMID 38574312, PMID 38780927, PMID 39235488, PMID 39281099, PMID 39551064, PMID 39938471, PMID 40789106
U10CA180868 (14), U10CA021661 (7), U10CA180820 (6), P30CA013330 (3), U10CA180886 (3), U10CA027469 (2), U10CA098543 (2), UG1CA189867 (2), K12CA086913 (1), P01CA021239 (1), P30CA006516 (1), P30CA015083 (1), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1)